Increasing Prevalence of Cannabinoid Hyperemesis Syndrome in Young Adults and Minority Populations.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40511929.
- Also identified by DOI 10.14309/ajg.0000000000003591.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prevalence rates for cannabinoid hyperemesis syndrome (CHS) across demographic groups remain unclear. We used data from the Massachusetts Center for Health Information and Analysis to estimate the rates of CHS from 2012 to 2021, across >15 million emergency department visits and demographic groups. CHS cases per 10,000 emergency department visits increased from 0.729 to 10.6 in Massachusetts (2012-2021). Individuals aged 18-34 years experienced the fastest rise in CHS prevalence, with young adults, Hispanic individuals, Black individuals, and men having the overall highest 10-year prevalence. Younger adults, Hispanic individuals, and Black individuals may be at higher risk for presenting with CHS.
Medical subject headings
- Cannabinoids
- Minority Groups
- Vomiting